Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.

PubWeight™: 1.70‹?› | Rank: Top 3%

🔗 View Article (PMID 10217584)

Published in Vaccine on April 09, 1999

Authors

T P Monath1, K Soike, I Levenbook, Z X Zhang, J Arroyo, S Delagrave, G Myers, A D Barrett, R E Shope, M Ratterree, T J Chambers, F Guirakhoo

Author Affiliations

1: OraVax Inc., Cambridge, MA 02139, USA. tmonath@oravax.com

Articles citing this

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol (2004) 1.99

Japanese encephalitis-a pathological and clinical perspective. PLoS Negl Trop Dis (2009) 1.82

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol (2000) 1.79

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol (2000) 1.79

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol (2001) 1.73

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol (2000) 1.64

Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol (2002) 1.61

Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. J Virol (2000) 1.56

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol (2004) 1.50

Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol (2000) 1.35

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol (2001) 1.32

High fidelity of yellow fever virus RNA polymerase. J Virol (2004) 1.31

Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis (2008) 1.23

Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein. J Virol (2001) 1.19

Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol (2000) 1.18

Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine (2011) 1.15

Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J Virol (2003) 1.05

Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol (2009) 1.04

Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus. J Neurovirol (2014) 0.98

Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine (2007) 0.97

Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol (1999) 0.97

Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother (2013) 0.93

Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice. J Virol (2004) 0.92

Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine (2008) 0.90

Quasispecies of dengue virus. Trop Med Health (2011) 0.89

Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin (2010) 0.86

Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virus. J Med Virol (2011) 0.85

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine (2014) 0.84

A review of vaccine approaches for West Nile virus. Int J Environ Res Public Health (2013) 0.83

Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys. Vaccine (2008) 0.83

Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother (2017) 0.82

Exploring of primate models of tick-borne flaviviruses infection for evaluation of vaccines and drugs efficacy. PLoS One (2013) 0.80

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin (2010) 0.79

Japanese Encephalitis Vaccines. J Bioterror Biodef (2011) 0.79

High-throughput automated image analysis of neuroinflammation and neurodegeneration enables quantitative assessment of virus neurovirulence. Vaccine (2010) 0.79

Neuropathogenesis and neurovirulence of live flaviviral vaccines in monkeys. J Virol (2009) 0.78

Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence. J Virol (2016) 0.75

The chimeric Japanese encephalitis/Dengue 2 virus protects mice from challenge by both dengue virus and JEV virulent virus. Protein Cell (2017) 0.75

T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models. Viruses (2017) 0.75

Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. J Gen Virol (2014) 0.75

Articles by these authors

Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum (1977) 9.14

SWINE INFLUENZA : II. A HEMOPHILIC BACILLUS FROM THE RESPIRATORY TRACT OF INFECTED SWINE. J Exp Med (1931) 9.13

NEUTRALIZATION TESTS WITH SERA OF CONVALESCENT OR IMMUNIZED ANIMALS AND THE VIRUSES OF SWINE AND HUMAN INFLUENZA. J Exp Med (1936) 8.25

Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol (1989) 7.06

Transmission of human immunodeficiency virus in a dental practice. Ann Intern Med (1992) 5.36

Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol (1989) 4.46

Neurologic abnormalities of Lyme disease. Medicine (Baltimore) (1979) 3.98

THE ETIOLOGY OF SWINE INFLUENZA. Science (1931) 3.88

AN INTERMEDIATE HOST FOR THE SWINE INFLUENZA VIRUS. Science (1939) 3.87

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol (1998) 3.77

Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol (2000) 3.21

Molecular epidemiology of HIV transmission in a dental practice. Science (1992) 3.10

"MAD ITCH" OF CATTLE. Science (1930) 2.90

Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses (1992) 2.72

TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68

Two African viruses serologically and morphologically related to rabies virus. J Virol (1970) 2.62

Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J Virol (1989) 2.59

Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol (2001) 2.59

Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol (1987) 2.59

Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site. J Virol (1993) 2.56

Bunyaviridae. Intervirology (1980) 2.53

Thottapalayam virus: a presumptive arbovirus isolated from a shrew in India. Indian J Med Res (1971) 2.52

Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. Cancer Res (1985) 2.42

Oligonucleotide fingerprints of RNA species obtained from rhabdoviruses belonging to the vesicular stomatitis virus subgroup. J Virol (1977) 2.35

Resorption of bone by isolated rabbit osteoclasts. J Cell Sci (1984) 2.33

Phylogeny of the Simbu serogroup of the genus Bunyavirus. J Gen Virol (2001) 2.30

PSEUDORABIES AS A CONTAGIOUS DISEASE IN SWINE. Science (1934) 2.27

A protein kinase gene complements the lytic phenotype of Saccharomyces cerevisiae lyt2 mutants. Mol Microbiol (1991) 2.19

Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17

Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15

Effects of standing position on spontaneous uterine contractility and other aspects of labor. J Perinat Med (1975) 2.15

Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology (1996) 2.09

Rate and pattern of epithelial cell proliferation in ulcerative colitis. Gut (1981) 2.08

Calcitonin alters behaviour of isolated osteoclasts. J Pathol (1982) 2.06

Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol (1994) 2.06

Multinucleate giant cells. J Pathol (1978) 2.04

Colonic adenomas--a colonoscopy survey. Gut (1979) 2.01

Detection of antibodies to alphaviruses by enzyme-linked immunosorbent assay. J Clin Microbiol (1979) 2.01

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol (2004) 1.99

Proposed antigenic classification of registered arboviruses I. Togaviridae, Alphavirus. Intervirology (1980) 1.98

Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet (2000) 1.96

Venezuelan haemorrhagic fever. Lancet (1991) 1.90

The phylogenetic history of immunodeficiency viruses. Nature (1988) 1.89

Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med (1997) 1.89

Formation of recombinants between snowshoe hare and La Crosse bunyaviruses. J Virol (1977) 1.87

Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. Virology (1996) 1.87

Epidemiological aspects of the 1969 yellow fever epidemic in Nigeria. Bull World Health Organ (1972) 1.86

Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol (1986) 1.83

Genetic and antigenic diversity among eastern equine encephalitis viruses from North, Central, and South America. Am J Trop Med Hyg (1999) 1.83

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol (2000) 1.79

A system for pattern matching applications on biosequences. Comput Appl Biosci (1993) 1.79

A novel hantavirus associated with an outbreak of fatal respiratory disease in the southwestern United States: evolutionary relationships to known hantaviruses. J Virol (1994) 1.78

Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78

THE ANTIBODY RESPONSE TO SWINE INFLUENZA. J Exp Med (1939) 1.77

Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol (2001) 1.73

Genetic variation in the 3' non-coding region of dengue viruses. Virology (2001) 1.71

Nucleotide sequences and phylogeny of the nucleocapsid gene of Oropouche virus. J Gen Virol (2000) 1.70

Mutagenesis of conserved residues at the yellow fever virus 3/4A and 4B/5 dibasic cleavage sites: effects on cleavage efficiency and polyprotein processing. Virology (1993) 1.70

Applications of flow cytometry to clinical microbiology. Clin Microbiol Rev (2000) 1.69

Electron microscopic and antigenic studies of uncharacterized viruses. II. Evidence suggesting the placement of viruses in the family Bunyaviridae. Arch Virol (1989) 1.67

Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet (1997) 1.65

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol (2000) 1.64

Mutagenesis of the yellow fever virus NS2A/2B cleavage site: effects on proteolytic processing, viral replication, and evidence for alternative processing of the NS2A protein. Virology (1994) 1.63

Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J Exp Med (1993) 1.63

An antiviral substance from Penicillium funiculosum. V. Induction of interferon by helenine. J Exp Med (1966) 1.63

Detection of La Crosse arbovirus antigen in mosquito pools: application of chromogenic and fluorogenic enzyme immunoassay systems. J Clin Microbiol (1982) 1.62

A model study of the use of monoclonal antibodies in capture enzyme immunoassays for antigen quantification exploiting the epitope map of tick-borne encephalitis virus. J Biol Stand (1986) 1.62

Heart rate variability and sudden death secondary to coronary artery disease during ambulatory electrocardiographic monitoring. Am J Cardiol (1987) 1.62

A CHANGE IN RABBIT FIBROMA VIRUS SUGGESTING MUTATION : III. INTERPRETATION OF FINDINGS. J Exp Med (1936) 1.61

A distinct African lentivirus from Sykes' monkeys. J Virol (1993) 1.58

Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology (1999) 1.56

Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55

Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol (1986) 1.55

The granuloma in Crohn's disease. Gut (1979) 1.54

Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa. Virology (1996) 1.53

Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology (1986) 1.52

Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies. J Gen Virol (1985) 1.50